JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
Purpose of this study
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Inclusion Criteria:
- Age greater than or equal to (>=) 60 years old
- Biopsy-confirmed squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or supraglottic larynx and a candidate for definitive radiation therapy with or without cetuximab
- Clinical stage T3-4 NX or T2 N2-3 disease according to the 8th edition of AJCC
- One primary tumor lesion amendable for intratumoral injection
- Ineligible to receive platinum-based chemotherapy with radiation (at least one of the following):
1. Estimated creatinine clearance >= 30 and less than (<) 50 milliliters/minute (mL/min) (per Cockcroft-Gault equation),
2. Grade >= 2 hearing loss or tinnitus,
3. Grade >= 2 peripheral neuropathy,
4. New York Heart Association Class 3
5. Aged 70-74 years old with Geriatric 8 (G8) score less than or equal to (<=) 14 or Aged >= 75 years old
- Eastern cooperative oncology group (ECOG) performance status 0 to 1
- Life expectancy >= 6 months
Exclusion Criteria:
- Carcinoma of the nasopharynx, paranasal sinus, salivary gland, or thyroid gland; or non-squamous histology or SCC of unknown primary origin
- Clinical stage T1-2 N0, T2 N1, or M1 disease according to the 8th edition of AJCC
- Loco-regionally recurrent head & neck cancer that has been previously treated with surgery, radiation therapy, and/or chemotherapy
- Prior or concurrent primary malignancy (including second synchronous head & neck cancer) within the last 2 years of informed consent and whose natural history has the potential to interfere with the safety and efficacy assessment of the investigational agent
- Ongoing or active infection requiring treatment with antimicrobial therapy within 2 weeks of randomization
Primary Outcome Measures:
- Progression-free Survival (PFS) Based on Independent Central Review (ICR) [Time Frame: 30 months following first randomized participant]
- PFS is defined as time from randomization to local-regional progression (including recurrence), distant progression, or death from any cause, whichever occurs first.
Secondary Outcome Measures:
- Overall Survival (OS) [Time Frame: 48 months following first randomized participant]
- Time from randomization to death from any cause.
- Local-regional control [Time Frame: 48 months following first randomized participant]
- Time to local regional progression: time from randomization to local-regional progression (including recurrence) or death, whichever occurs first.
- Distant control [Time Frame: 48 months following first randomized participant]
- Time to distant progression: time from randomization to distant progression or death, whichever occurs first.
- Quality of Life over time - QLQ H&N35 [Time Frame: 48 months following first randomized participant]
- Change from baseline over time in symptoms, function, and health related QOL using the European organisation for research and treatment of cancer (EORTC) questionnaire-head and neck cancer module (QLQ H&N35).
- Quality of Life over time - EQ 5D 5L [Time Frame: 48 months following first randomized participant]
- Change from baseline over time in symptoms, function, and health related QOL using the 5 level EuroQol 5 dimension (EQ 5D 5L) instrument.
- Safety across duration of study - AEs [Time Frame: 48 months following first randomized participant]
- Adverse events (AEs).
- Objective Response Rate (ORR) [Time Frame: 48 months following first randomized participant]
- Rate of complete response (CR)+partial response (PR) [RESIST 1.1].
- Duration of Overall Response [Time Frame: 48 months following first randomized participant]
- Time from CR or PR to progression of disease, unequivocal clinical progression, or death, whichever occurs first.
- Head and Neck Cancer Specific Event-Free Survival [Time Frame: 48 months following first randomized participant]
- Time from randomization to loco regional progression (including recurrence), distant progression, or head and neck cancer related death, as per RECIST 1.1, whichever occurs first.
- Head and Neck Cancer-Specific Survival [Time Frame: 48 months following first randomized participant]
- Time from randomization to head and neck cancer-related death.
Study Locations in Europe: Austria, Belgium, Bulgaria, Croatia, Czechia, Finland, France, Germany, Greece, Hungary, Portugal, Romania, Serbia, Spain, Sweden, United Kingdom
Estimated Enrollment: 500 patients
Estimated Study Completion Date: 2028-06-30
More Information: NCT04892173


